Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02492620 · ClinicalTrials.gov registry record · Phase 3
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
A Phase 3 study of Chronic Kidney Disease and Iron Deficiency Anemia, sponsored by Denver Nephrologists, P.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT02492620: Completed Phase 3 study of Chronic Kidney Disease and Iron Deficiency Anemia, sponsored by Denver Nephrologists, P.C..
NCT02492620 is a Phase 3 study of Chronic Kidney Disease and Iron Deficiency Anemia that has completed, run by Denver Nephrologists, P.C.. The registered enrollment target is 200 participants, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02492620, a Phase 3 study of Chronic Kidney Disease and Iron Deficiency Anemia, has completed, sponsored by Denver Nephrologists, P.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will result in a reduced need for ESA and intravenous iron. The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning, reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy.
Conditions Studied
Interventions
- DRUG Ferric Citrate
Study Locations (1)
Colorado
- Denver Nephrologists, P.C. - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-11 |
| Phase | Phase 3 |
What the finished NCT02492620 record still lists
NCT02492620 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (94% lower).
The record links to 4 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Ferric Citrate is the first listed.
NCT02492620 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT02492620 about?
NCT02492620 is a clinical study titled "Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D". It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will res...
What is the current status of trial NCT02492620?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2015-03. Estimated completion is 2017-11.
What conditions does trial NCT02492620 study?
This clinical trial studies the following conditions: Chronic Kidney Disease, Iron Deficiency Anemia, Renal Insufficiency, Hyperphosphatemia.
What interventions are being tested in trial NCT02492620?
The interventions under investigation include: Ferric Citrate (DRUG).
Who is sponsoring clinical trial NCT02492620?
This trial is sponsored by Denver Nephrologists, P.C., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02492620 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02492620's enrollment target sits among peer trials
200 39th of 101 higher than 63 of 101 other Chronic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-driven Management of BP in CKD
RECRUITING · Phase 3
-
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
RECRUITING · Phase 3
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RECRUITING · Phase 3
-
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia